New drug shrinks tumors in hard-to-treat blood cancers
NCT ID NCT02337829
First seen Jan 11, 2026 · Last updated May 16, 2026 · Updated 16 times
Summary
This study tested a drug called acalabrutinib in 48 adults with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who had a high-risk genetic change (deletion 17p). The goal was to see how well the drug shrank tumors. Results showed that many patients had a partial or complete response, meaning their cancer got smaller or disappeared for a time. This is a disease-control treatment, not a cure, as patients may need ongoing therapy.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC LYMPHOCYTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Research Site
Bethesda, Maryland, 20892, United States
Conditions
Explore the condition pages connected to this study.